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Abstract  1 
Objectives: To identify barriers to medication adherence in patients prescribed medicines for 2 
the prevention of cardiovascular disease and map these to the Theoretical Domains 3 
Framework (TDF), to produce a conceptual framework for developing a questionnaire-based 4 
medication adherence tool. 5 
Methods: A scoping review of barriers to medication adherence in long-term conditions was 6 
conducted to generate an initial pool of barriers.  After preliminary mapping to the TDF, these 7 
barriers were presented to two focus groups of patients prescribed medicines for the 8 
prevention of cardiovascular disease (n=14) to stimulate discussion.  The group discussions 9 
enabled the patients’ interpretations of the adherence barriers to be determined, provided 10 
validity from the patient perspective, and identified additional barriers unrepresented in the 11 
scoping review.  12 
Key findings: The preliminary pool of adherence barriers was identified from 47 studies 13 
across a range of long-term conditions.  The majority of TDF domains were represented by 14 
these literature-identified barriers except ‘social/professional role and identity’ and 15 
‘behavioural regulation’.  Barrier mapping was largely endorsed by focus group participants, 16 
who also contributed additional barriers, including those relating to not having a ‘system’ in 17 
place for managing their medicines and the negative emotions evoked by medicine taking. 18 
Conclusion: The TDF enabled full exploration of adherence barriers including those relating 19 
to emotions which have received limited attention in the literature.  This work has provided a 20 
conceptual framework for developing a questionnaire to identify an individual’s adherence 21 
barriers which may then be coupled with appropriate behaviour change techniques to deliver a 22 
theory-based intervention tailored for individual need.   23 
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Introduction 27 
An estimated 30 to 50% of patients with long-term conditions (LTCs) are non-adherent to 28 
their prescribed medicines.1 A large-scale meta-analysis, estimated adherence to medicines for 29 
the prevention of cardiovascular disease (CVD) to be 57% (95% CI 50-64%).2  These 30 
medicines are prescribed for a range of  LTCs including hypertension, dyslipidaemia and 31 
angina and are amongst the most commonly prescribed medicines in the UK.2   32 
Medication adherence is a complex health behaviour, influenced by a plethora of factors.3 33 
Non-adherence can diminish treatment effects leading to increased morbidity and mortality4 34 
plus wasted healthcare resources.3 Evidence suggests that a greater understanding of the 35 
barriers to adherence is needed to improve the effectiveness of adherence interventions.5  A 36 
plethora of theoretical models have been developed to explain the complexities of medication 37 
adherence, including those focused on the balance between patient perceived necessity and 38 
concerns about medicines6 and those focused on the importance of practitioner consultation 39 
style7. Though these models highlight important considerations for medication adherence 40 
research, the most recent Cochrane review highlights that meaningful progress with adherence 41 
research is still sub-optimal. 5 Theoretical models such as Social Cognitive Theory, the Health 42 
Belief Model and Self-regulation model have been applied to medication adherence 43 
interventions.8  However, a systematic review of theory-based interventions to improve 44 
medication adherence identified that none have successfully guided the development of an 45 
effective adherence intervention applicable to all long-term medications8. 46 
Psychology-based behaviour change techniques, such as motivational interviewing, show 47 
promise as effective adherence interventions.9  However, core training of the existing 48 
healthcare workforce is not designed to equip practitioners in selecting the most appropriate 49 
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behaviour change techniques (BCT) for improving adherence, according to identified 50 
individual adherence barriers.10,11,12,  51 
Developing an adherence tool which identifies a patient’s barriers to adherence and guides the 52 
practitioner to work with the patient to select the most appropriate BCTs may enable the 53 
healthcare workforce to respond to the call for theory and evidence guided, individualised 54 
interventions, 13, 14, which identify potential barriers to behaviour change. 8, 155,  55 
The Theoretical Domains Framework (TDF)16, 17 is a composite of health psychology theory 56 
which offers a structured approach for exploring the determinants of individual behaviour.18  57 
The domains of the TDF have been linked to evidence-based BCTs,19,20 leading to successful 58 
use of the TDF to guide the intervention development for behaviour change.21  The TDF may 59 
therefore be suitable for mapping adherence barriers and creating a conceptual framework.  60 
Literature describing application of the TDF to medication adherence22-25 represents notable 61 
advancements in the field.  However, each study focusses on medication adherence in a 62 
specific disease rather than multiple LTCs.  Most patients have multiple diseases for which 63 
they are prescribed multiple medicines; routine practice consultations such as medication 64 
reviews are therefore not focused on medication adherence in one specific disease state.  65 
Intervention implementation is supported by compatibility with routine practice,26 thus, an 66 
adherence support tool applicable across a range of LTCs is a stronger candidate for effective 67 
implementation into routine practice.27 Exploration of barriers to adherence in medicines 68 
prescribed for the prevention of CVD (which covers multiple LTCs) is therefore an intuitive 69 
opportunity to broaden TDF-based adherence research towards multiple LTCs, whilst 70 
minimising the confounding factors that could be introduced by considering all LTCs 71 
collectively.  72 
5 
 
The current article presents the developmental work which underpinned  the Identification of 73 
Medication Adherence Barriers Questionnaire (IMAB-Q); 28 a TDF-based questionnaire to 74 
support practitioners in identifying non-adherent patient’s and elucidating their individual 75 
reasons for non-adherence. It comprises a scoping review of barriers to adherence in LTCs, 76 
the initial mapping of these barriers to the TDF and the qualitative exploration of these 77 
barriers in patients prescribed medicines for the prevention of CVD, in order to develop a 78 
conceptual framework to inform questionnaire development.  79 
Existing literature syntheses (e.g.29,30) report quantitative findings from intervention studies 80 
and non-modifiable adherence determinants such as age, gender and socioeconomic status.  81 
Modifiable determinants of adherence, relating to psychosocial and environmental barriers are 82 
often overlooked.  These reviews also consider non-adherence in all conditions, yet important 83 
differences in adherence determinants exist between acute and LTCs.3  A broader evidence 84 
synthesis, narratively combining both quantitative and qualitative studies may therefore 85 
provide a better foundation for exploring adherence barriers.  Scoping reviews are an 86 
appropriate method to ‘map’ relevant literature and address broad topics where differing study 87 
designs are available.31   88 
Correct mapping of adherence barriers to a theoretical framework requires deep understanding 89 
which cannot always be elucidated from the literature.  Qualitative exploration to supplement 90 
a literature review can provide this depth of understanding,32 enhance the utility of a scoping 91 
review and ensure meaningful mapping.   92 
 93 
Methods 94 
 95 
The programme of work included four phases: 96 
1. Scoping review of barriers to medication adherence in LTCs 97 
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2. Preliminary mapping of literature-identified barriers to the TDF 98 
3. Focus groups with patients prescribed medicines for the prevention of CVD 99 
4. Refinement of adherence barriers mapping 100 
Phase 1 Scoping review  101 
This phase aimed to generate a preliminary repository of barriers to medication adherence in 102 
LTCs, for stimulating focus group discussions.   103 
Search strategy 104 
The Embase, Medline and PsychINFO databases were accessed via the Ovid interface on 18th 105 
September 2012, to undertake the search detailed in supplementary file 1.  The search was 106 
restricted to articles written in English and since 2005, as scoping searches indicated that prior 107 
to this, psychosocial determinants of adherence were seldom explored. Abstracts were 108 
screened against pre-defined inclusion and exclusion criteria.  109 
Inclusion and exclusion criteria 110 
Abstracts of any study design, reporting medication adherence barriers in LTCs were eligible 111 
for inclusion.  LTCs beyond those covered by ‘CVD prevention’ were included to ensure 112 
breadth of the preliminary pool of adherence barriers before later refinement.  113 
Abstracts were excluded if they: 114 
 Included participants with drug addiction or mental health problems (the nature of non-115 
adherence in this population is condition-specific) 116 
Data collection and synthesis (charting) 117 
7 
 
Full texts were accessed where possible, but when unavailable, adherence barriers were 118 
extracted from abstracts.  Adherence barriers were initially recorded using the exact 119 
terminology in the article.  Once all barriers had been extracted, barriers with the same 120 
underpinning characteristic but presented differently due to specifics of context or variations 121 
in language were grouped, for example ‘forgetting to take medicines’ and ‘not remembering 122 
doses’ were grouped as one barrier related to forgetting medicines.  123 
Phase 2 Mapping of adherence barriers to the TDF 124 
Adherence barriers were mapped to one of the 12 domains of the original TDF.16  .  Existing 125 
literature16, 17, 33 were utilised to interpret each of the TDF domains in the context of barriers 126 
to medication adherence. Preliminary mapping was discussed by the authors until consensus 127 
was achieved about which barriers belonged to each domain.   128 
Phase 3 Focus groups with patients prescribed medicines for the prevention of CVD 129 
Focus groups with patients prescribed medication for CVD prevention were undertaken to: 130 
1. Identify additional adherence barriers not elicited from the scoping review 131 
2. Optimise the research team’s understanding of identified barriers 132 
3. Ensure appropriate mapping of barriers to the TDF 133 
Participants and recruitment  134 
Recruitment commenced post ethical approval from the University of East Anglia Faculty of 135 
Health ethics committee (reference number 2012/2013-04).  The large pool of employees and 136 
students at the university were used as potential participants and gatekeepers to the wider non-137 
university community for recruitment.  Recruitment was via posters placed across campus, a 138 
weekly e-bulletin emailed to all staff and students, and university social media.  139 
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Advertisements were worded to extend recruitment beyond university students and staff, to 140 
include their friends and family, thus increasing the likelihood of recruiting a diverse 141 
population.  Participants were offered a £10 high street shopping voucher for participation.   142 
Inclusion and exclusion criteria 143 
Adults (individuals aged 18 years or older) able to provide informed consent were eligible if 144 
prescribed medication for the prevention of CVD as defined in the literature.2  Those who 145 
were unable to read or speak English, or receiving medication for the treatment of addiction 146 
or mental illness were excluded. 147 
Procedures   148 
Eligible members of the public expressing interest in participation were posted a study 149 
information leaflet, consent form and brief questionnaire to collect demographic information, 150 
plus the number of medicines prescribed and prescription charge exemption status.  Returned 151 
consent forms and questionnaires were used to assign participants to one of two focus groups.  152 
Two focus groups, each with six to eight participants was deemed to be appropriate for 153 
generating sufficient data for the exploratory nature of this stage, whilst not over-burdening 154 
members of the public. Recruitment continued until each focus group had between six and 155 
eight participants representing a range of demographic characteristics.  156 
 157 
Focus groups 158 
Each focus group was audio-recorded, approximately two hours long, transcribed verbatim 159 
and moderated by the lead author with co-facilitation.  The TDF-domains deemed applicable 160 
to medication adherence barriers (established in phase one) were divided across the two focus 161 
groups. Adherence barriers mapped to differing behavioural domains were considered in each 162 
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focus group but the ‘emotions’ domain was duplicated to investigate consistency of 163 
interpretation between participants of the two focus groups.  This domain was selected for 164 
duplication across both focus groups as it was considered to be the domain most likely 165 
influenced by differing personal experience; we therefore aimed to explore how these 166 
personal experiences differed across the largest possible number of participants.  167 
Each behavioural domain was described to participants in turn, before discussing the 168 
literature-identified adherence barriers mapped to the domain.  The initial mapping of barriers 169 
to each domain of the TDF is provided in supplementary file 4; this mapping therefore served 170 
as the topic guide for the focus groups.  Participants were encouraged to share their 171 
experiences and thoughts, using the adherence barriers presented as prompts for discussion.  172 
For each behavioural domain, participants were asked if there were any additional adherence 173 
barriers that were not represented.   174 
Data analysis 175 
Primary data analysis was undertaken by the lead author then validated by the co-authors as 176 
recommended in the literature.34  Data were analysed using a framework approach,35based 177 
upon the domains of the TDF.  178 
Phase 4 Refinement of adherence barriers mapped to the TDF and summary 179 
Data from the focus groups were used to refine the mapping of adherence barriers, according 180 
to the participants’ understanding of their meaning and relevance.  Any additional barriers 181 
generated during the consultation exercises were also considered.   182 
Results 183 
Phase 1 Scoping review 184 
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Forty-seven eligible studies (representing a range of LTCs) were identified, from which the 185 
preliminary pool of adherence barriers were extracted.  Similar barriers were initially grouped 186 
into 17 themes, (as summarised in supplementary file 2) which included beliefs, cognitive and 187 
memory associated factors, knowledge-related factors and administration problems.  188 
Phase 2 Mapping of adherence barriers to the TDF 189 
The agreed interpretations of how each behavioural domain of the TDF relates to medication 190 
adherence barriers are provided in supplementary file 3.  All adherence barriers were 191 
considered carefully, though some required a deeper level of consideration and discussion. An 192 
interesting example here is the adherence barrier ‘experience of side effects’ which was 193 
ultimately mapped to the ‘beliefs about capabilities’ domain of the TDF. This decision was 194 
reflective of the recognition that it is not the side effects per se that influence medication 195 
adherence, but more an individual’s ability to appropriately cope with the medication side 196 
effect that determines their behaviour.  The ‘skills’ domain was considered to encompass both 197 
physical skills, (e.g. medicines administration) and cognitive skills (e.g. processing and 198 
understanding instructions).  A number of barriers such as ‘being too busy’ and ‘having a 199 
chaotic lifestyle’ related to competing goals; these barriers did not intuitively map onto any of 200 
the existing behavioural domains of the TDF.  Guided by relevant literature,33 an additional 201 
behavioural domain termed ‘goal conflicts’ was created.  The behavioural domains termed 202 
‘social/professional role and identity’ and ‘behavioural regulation’ were excluded as no 203 
literature identified adherence barriers were mapped to these domains.  The constructs 204 
associated with the ‘behavioural regulation’ domain are barriers and facilitators to 205 
behaviour16; as the study was focused on barriers to medication adherence, the ‘behavioural 206 
regulation’ domain was redundant.  The ‘nature of the behaviour’ domain was also excluded; 207 
Michie et al16 explain that this domain is accorded to a different order as it describes the 208 
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dependent variable, in this case, taking medicines as prescribed.36  It is therefore not treated as 209 
a domain of behaviour change, but its constructs such as habits, were considered throughout 210 
the mapping task.  Of the original 12 domain TDF, the three domains of ‘social/professional 211 
role and identity’, ‘behavioural regulation’ and ‘nature of the behaviour’ were not therefore 212 
active in the context of medication adherence barriers and an additional ‘goal conflicts 213 
domain’ was generated yielding 10 active domains in the present study.  214 
The adherence barriers initially grouped to each TDF domain are detailed in supplementary 215 
file 4.  Barriers were well distributed across the 10 relevant domains, though the beliefs about 216 
capabilities, beliefs about consequences and social influences domains had the broadest range 217 
of adherence barriers.  Some barriers, for example ‘no medical insurance’ were excluded as 218 
they were not relevant to the UK healthcare system. 219 
Phase 3 Focus groups with medicine-taking members of the public 220 
Interest in focus group participation was expressed by 32 members of the public; signed 221 
consent forms and demographic questionnaires were returned by 17 (54.8%) respondents, of 222 
whom, 14 (82.4%) were able to attend one of the two focus groups.  Table 1 summarises the 223 
participant’s descriptive characteristics.  Across all participants, there was a relatively even 224 
gender split and a median (IQR) age of 62.0 (51.5, 75.5) years.  The majority of participants 225 
were exempt from prescription charges and most were prescribed multiple medicines; the 226 
median (IQR) number was 3 (1.5, 6).  Only three participants (21.4%) were students or 227 
employees of the university. 228 
[Table 1 about here]  229 
Participant discussions demonstrated an understanding of the TDF and agreement with the 230 
mapping process.. Participants discussed adherence barriers known through personal 231 
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experience as well as offering opinion on potential adherence barriers that others may 232 
experience.  233 
Focus group one 234 
A summary of topics discussed is provided in supplementary file 5.  Topics were discussed 235 
across all six TDF domains presented in this focus group. Three adherence barriers, 236 
undetected by the scoping review were discussed: 237 
 Not knowing about medicine delivery and repeat ordering systems – mapped to the 238 
knowledge domain 239 
 Difficulties with identifying medicines, especially when the brands and packaging 240 
regularly change – mapped to the skills domain 241 
 Hostility from GP receptionists which can prohibit medicine access – mapped to the social 242 
influences domain 243 
Focus group two 244 
A summary of the topics of participant discussion is provided in supplementary file 6. Topics 245 
were discussed across all five behavioural domains presented but the beliefs about 246 
consequences domain was particularly stimulating of discussion.  Adherence barriers 247 
discussed by participants undetected by the scoping review were: 248 
 Negative emotions caused by feelings of getting a ‘raw deal’ with regards to medicines 249 
supply, e.g. only getting one month’s worth of medicines when others get three months’ – 250 
mapped to the emotions domain 251 
 Reduced motivation to adhere caused by questioning whether medicines represent ‘good 252 
value for money’ – mapped to the motivation and goals domain 253 
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 ‘Annoyance’ about medicines taking when medicines have to be declared on insurance 254 
forms – mapped to the emotions domain. 255 
 256 
The emotions domain was discussed in both focus groups, whilst there were similarities in the 257 
discussions on this topic between the two focus groups, differing personal experiences meant 258 
that in the second focus group, emotions related to ‘annoyance’ and ‘getting a raw deal’ were 259 
discussed which were not raised within the first focus group. 260 
Phase 4 Refinement of adherence barriers mapped to the TDF 261 
A summary of the re-mapping of adherence barriers from one TDF domain to another due to 262 
the additional perspectives identified from the focus groups is provided in supplementary file 263 
7. Seventeen adherence barriers were re-mapped at this stage.  Some barriers, for example 264 
knowing how to identify tablets or access them from packaging were moved from the 265 
knowledge domain to the skills domain.  Additional understanding gained from the patients’ 266 
perspective meant that these behaviours could be understood as an ability that can be acquired 267 
through practice (skill), rather than direct knowledge.  Similarly, barriers such as feeling 268 
negative about medicines taking or burdened by this were originally conceived to relate to 269 
motivation and goals but understanding from the patient perspective enabled an appreciation 270 
of the genuine emotive aspects of these barriers.  271 
Table 2 summarises the adherence barriers mapped to the domains of the TDF16 highlighting 272 
the wide range of adherence barriers captured. 273 
[Table 2 near here] 274 
Discussion 275 
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Use of the TDF16 to both organise literature-identified barriers to adherence and structure 276 
focus group discussions has facilitated their detailed analysis.  It has identified ten active 277 
domains, each incorporating a range of determinants of medication adherence, such as those 278 
relating to emotions, which have previously received less attention in literature.29   279 
It is acknowledged that further relevant literature may have emerged since the conduct of the 280 
scoping review, however, its function was to act as a vehicle for prompting discussion in the 281 
focus groups. Given that the scoping review was designed to be supplemented by qualitative 282 
work and not intended to quantify the importance or prevalence of different barriers to 283 
adherence a full systematic review was inappropriate. The new adherence barriers and 284 
changes in mapping arising from the focus groups indicate that the methodological approach 285 
was appropriate for initiating and structuring the discussions.   286 
Recruitment through university advertisements for the focus groups may have introduced 287 
biases.  However, participants represented a wide range of ages and medication regimen 288 
complexities.  Furthermore, only three participants were university students or employees, of 289 
which only one was an academic.  Whilst anecdotal evidence gathered from the focus group 290 
discussions means that we are confident that a wide range of educational and professional 291 
backgrounds were covered in our sample of focus group participants, characterisation of 292 
participants through formal data collection about educational level may have added further 293 
rigour.  Additional information regarding whether adherence barriers suggested by focus 294 
group participants were based upon personal experience or supposition, may have been 295 
beneficial and provided readers with further contextual information.  296 
No relevant adherence barriers were identified for three of the TDF domains and a new 297 
domain termed ‘goal conflicts’ was added to capture adherence barriers that were not 298 
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reflected by the 2005 version of the TDF.  The appropriateness of the adaptation is confirmed 299 
by the updated version of the TDF,17 which now incorporates goal conflicts. 300 
Contrary to the present paper which mapped adherence barriers to all bar three of the TDF 301 
domains, Presseau et al.22 report that fewer TDF domains were relevant and did not map 302 
adherence barriers to the skills, beliefs about capabilities, motivation and goals, 303 
environmental context or emotions domains.  Differing methodological approaches may 304 
account for this as Presseau and colleagues sought to identify the most relevant domains 305 
whereas the present article sought to explore the breadth of determinants.  The latter approach 306 
has allowed exploration of adherence barriers which are often overlooked.   A further 307 
difference is that Presseau and colleagues included the social/professional role and identity 308 
domain which was excluded from the present paper.  Crayton et al.23 also report redundancy 309 
of this domain when exploring adherence determinants in stroke survivors, as do Voshaar et 310 
al.24 with regards to adherence barriers and facilitators for disease-modifying anti rheumatic 311 
drugs.  In the present paper the social norms domain was used for barriers associated with not 312 
identifying oneself as a medicines taker.  These minor differences in mapping highlight that 313 
despite robustly employed methods, there is still inherent subjectivity in TDF interpretation.  314 
The inherent subjectivity of the TDF mapping process means that a different theoretical map 315 
could have been produced by other researchers, as highlighted by the work reported by 316 
Presseau et al.22 The mapping decision being undertaken by a research team with expertise in 317 
behavioural science and medication adherence plus refinement of this mapping based on 318 
patient input provides some confidence in the final map.  However, further validation of the 319 
mapping decisions by an independent peer with expertise in these fields may have added 320 
further rigour. 321 
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Crayton et al.23 highlight that ‘emotions’, ‘beliefs about consequences’ and ‘knowledge’ 322 
appeared to be most influential TDF domains when mapping adherence determinants in stroke 323 
survivors.  This finding is consistent with the qualitative explorations reported in this present 324 
paper.  Voshaar et al.24 also report mapping of adherence barriers across the range of TDF 325 
domains, with notable consistency in mapping compared to the work presented in the present 326 
paper.  Both studies therefore support applicability of the work presented in the current 327 
article, beyond CVD prevention.   328 
The studies reporting mapping of adherence barriers to the TDF22-24 provide useful 329 
contextualisation of the present work and highlight the similarities of adherence barriers 330 
across a range of LTCs.  However, the utility of each of these studies for adoption as routine 331 
practice is limited by their focus on specific diseases.  The present paper presents the first 332 
TDF-based conceptual framework of medication adherence barriers across multiple LTCs, 333 
and is also the first paper to develop a framework based on both literature-identified and 334 
qualitatively explored adherence barriers. 335 
The focus groups in the present study, added richness to the data and, despite a large body of 336 
existing literature regarding adherence barriers, new barriers were identified spanning a range 337 
of TDF domains.  An awareness of barriers such as a lack of knowledge about repeat 338 
prescription ordering services may be useful in supporting patients who wish to adhere but 339 
struggle with the management of their medicines.  Likewise, the information yielded about 340 
the range of negative emotions associated with medicines taking, adds to our knowledge of 341 
the factors that may influence a patient’s decisions to not adhere.  Emotions, such as feelings 342 
of frustration and being ‘short-changed’, may represent modifiable determinants of adherence 343 
worthy of further investigation as these are often overlooked29,37.  Practitioners seeking to 344 
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resolve non-adherence should be aware of the diverse plethora of factors that may influence 345 
adherence and mindful of the emotional components of medicines-taking behaviour.  346 
The present work creates an evidence-based platform for developing novel, theory guided 347 
interventions to improve medication adherence.  Whilst other theoretically informed 348 
adherence interventions have not always yielded improved outcomes,15,37 this may be 349 
influenced by the lack of guidance regarding how these theories should be used for 350 
intervention design.  The structured approach offered by the TDF and availability of work 351 
linking TDF domains to evidence based BCTs may address this difficulty.  A programme of 352 
work to develop a novel adherence intervention, based on this conceptual framework will 353 
follow.  Whilst theory guided litertaure20 can be utilised to match BCTS to the domains of the 354 
TDF, much work is needed in understanding how these BCTs are appliacable to medicines-355 
related consultations. Moreover, notable implementation work is necessary to explore how 356 
these BCTs are best delivered, from where and by whom.  357 
Conclusion 358 
This work provides the foundations for developing a patient questionnaire, grounded in the 359 
adherence barriers mapped to the TDF which will enable identification of an individual’s 360 
barriers to adherence.  As the focus groups were undertaken in the context of medicines 361 
prescribed for the prevention of CVD, it is intuitive to develop and trial a questionnaire in the 362 
same population.  However, as the literature-identified barriers discussed in these focus 363 
groups were sourced from a variety of LTCs, it is likely that the adherence barriers will also 364 
be applicable to medication non-adherence in other LTCs.  Further work is necessary to 365 
confirm this and to establish how adherence barriers vary for acute conditions.  366 
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Table 1:   Summary of participant characteristics for consultation exercises 
Participant characteristics Measure Consultation 
exercise one (n = 5) 
Consultation 
exercise two (n=9) 
Male gender  Number (%) 3 (60%) 5 (55.5%) 
Age (years)  Median (IQR) 70.0 (45.5, 76.5) 62.0 (54.0, 75.5) 
Exempt from prescription charges Number (%) 3 (60%) 6 (66.7%) 
Number of regularly prescribed medicines  Median, (IQR) 3 (1, 5) 2 (2, 6) 
Employed by the university Number (%) 2 (40%) 1 (11.1%) 
 
Table 2: Summary of adherence barriers mapped to each domain of the original TDF  
 
TDF Domain  Adherence barriers mapped to this domain 
Knowledge  Not knowing how to order prescriptions or about services that facilitate this process 
 Not knowing how to collect prescriptions or about services that facilitate this process 
 Having insufficient information about medicines e.g. how they work, why they were prescribed, side effects and benefits 
 Not knowing how (and when) to take medicines as prescribed 
Skills  Physical inability to take medicines as prescribed e.g. swallowing difficulties and problems accessing medicines from packaging 
 Cognitive inability to take medicines as prescribed e.g. inability to read and/or understand instructions 
 Inability to identify and differentiate between different medicines  
 Lack of organisational and forward planning skills (not having a system in place to help manage medicines) 
Beliefs about 
capabilities 
 Lack of confidence in ability to adhere and manage medicines e.g. feeling regimen is too complex 
 Lack of confidence to overcome difficulties with medicines taking e.g. experience of side effects 
 Perceived inability to cope with medicines related changes 
Beliefs about 
consequences 
 Fear that medicines will be (are) harmful  
 Belief that medicines cannot be trusted  
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 Doubting the efficacy of medicines 
 Not believing that there is a need for treatment 
 Denial of illness or non-acceptance of diagnosis 
 Decision making process justified belief about consequences (or lack of consideration of consequences) e.g. preference for 
alternative remedies 
Motivation and 
Goals 
 Not perceiving medicines taking as a priority 
 Lack of intention to adhere  
 Lack of motivation to adhere 
Goal Conflicts*  Cost of medicines (having to choose between paying for a prescription and something else) 
 Having a busy lifestyle (e.g. work and travel) and other priorities (e.g. family commitments or meal times) which impede medicines 
taking at specific times 
 Being too busy to order and collect prescriptions/having other priorities which impede ordering and collecting medicines 
Memory, attention & 
decision processes 
 Forgetting to take medicines  
 Forgetting to order/collect medicines from pharmacy  
 Lack of attention in medicines taking e.g. making errors or forgetting due to distractions 
Environmental 
context and 
resources 
 Problems with pharmacy/GP surgery e.g. not stocking medicines, lost prescriptions, failed orders etc. 
 Difficulties getting to pharmacy/GP surgery to collect prescriptions 
 Changes to environment or daily routine which impede medicines taking 
Social influences  Fear of judgement, discrimination or social stigma 
 Cultural and religious norms and expectations 
 Lack of trust in prescriber 
 Lack of social support 
Emotion   Experience of negative emotions associated with medicines taking e.g. frustration or embarrassment 
 Perceiving medicines taking as a negative reminder of illness/condition 
 Perceiving medicines taking as a burden 
Social/professional 
role & identity 
No adherence barriers mapped to this domain 
Behavioural 
regulation 
No adherence barriers mapped to this domain 
Nature of the 
behaviour 
No adherence barriers mapped to this domain 
 
* A newly created domain to reflect adherence barriers that did otherwise not fit 
